Add like
Add dislike
Add to saved papers

Series test of cluster and network analysis for lupus nephritis, before and after IFN-K-immunosuppressive therapy.

Nephrology 2018 November
AIM: The purpose was to screen potential targets of IFN-K-immunosuppressive therapy, which was used to offer effective information and resources for molecular targeted therapy.

METHODS: The gene expression profile of GSE72747 was used to screen out significant differently expressed genes (DEGs). Series Test of Cluster (STC) analysis for DEGs was performed. For all DEGs, the Database for Annotation, Visualization, and Integrated Discovery was performed for Gene Ontology (GO) enrichment analysis. Pathway enrichment analysis of DEGs was performed based on Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Pathway was constructed based on the interactions in the KEGG database. The coexpression network and gene signal expression networks were constructed and analyzed.

RESULTS: A total of 2193 DEGs were screened and eight significant profiles were identified. Significant GO terms included small molecule metabolic process, translation and apoptotic process. Metabolic pathways and Alzheimer's disease were significant KEGG pathways. Pathway relationship network of DEGs was constructed. MAPK signalling pathway, apoptosis and pathways in cancer were hub nodes. Gene co-expression network analysis was performed. VCP-interacting membrane protein and NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa were the hub nodes. Gene signal network was constructed with 162 nodes and 254 edges. Hub nodes were phospholipase C, beta 2.

CONCLUSION: Screened DEGs including VIMP, NDUFAB1, SEC61G, PSMC2 might be potential targets for lupus nephritis treatment by involving in different functions and pathways, such as metabolic process and immune process.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app